Myelosuppression Clinical Trial
Official title:
Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity
NCT number | NCT05442177 |
Other study ID # | REC104-12 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2015 |
Est. completion date | June 30, 2016 |
Verified date | June 2022 |
Source | Taichung Tzu Chi Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.
Status | Completed |
Enrollment | 35 |
Est. completion date | June 30, 2016 |
Est. primary completion date | June 30, 2016 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with cancer diagnosed through pathological histology - Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine - Patients with an Eastern Cooperative Oncology Group Performance score of 0-2 - Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function - Patients who were voluntarily involved in this study Exclusion Criteria: - Cases that did not meet the inclusion criteria - Patients who could not cooperate with pulse diagnosis - Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc. - Patients with severe infection - Patients with severe cachexia |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Taichung Tzu Chi Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chemotherapy-induced Hematologic Toxicity | the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression | one month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00524797 -
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
|
N/A | |
Completed |
NCT00151866 -
Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
|
Phase 3 | |
Recruiting |
NCT03126890 -
Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions
|
||
Completed |
NCT02692742 -
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
|
Phase 2 | |
Terminated |
NCT02375334 -
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
|
||
Not yet recruiting |
NCT03846414 -
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
|
||
Recruiting |
NCT04905329 -
A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
|
||
Not yet recruiting |
NCT05780294 -
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
|
Phase 3 |